Fig. 5. Blocking of NF-κB pathway sensitizes BETi-resistant CRC cells to JQ1 treatment.

a CRC cells were treated with JQ1 (1 μM) for 24 h and subjected to NF-κB reporter assay. b HCT116 and LoVo cells were treated with JQ1 (1 μM), Bortezomib (5 nM), or JQ1+Bortezomib for 24 h and subjected to NF-κB reporter assay. c HCT116 and LoVo were treated concurrently with JQ1 and BMS345541 at the indicated concentrations for 72 h. Cell viability was measured by CCK8. The synergistic cytotoxicity was quantitatively analyzed by CI. d HCT116 and LoVo cells were transfected with IKK1/2 siRNA for 2 days, then cells were treated with JQ1 (1 μM) for another 72 h. Cell viability was measured by CCK8. e RKO cells were transfected with IκBα siRNA for 2 days, then cells were treated with JQ1 (1 μM) for another 72 h. Cell viability was measured by CCK8. f mRNA alteration of FOXM1 in HCT116 and LoVo cells transfected with BRD2/3/4, IKK1/2, or BRD2/3/4+IKK1/2 siRNA for 72 h